<SEC-DOCUMENT>0001193125-20-281616.txt : 20201030
<SEC-HEADER>0001193125-20-281616.hdr.sgml : 20201030
<ACCEPTANCE-DATETIME>20201030060628
ACCESSION NUMBER:		0001193125-20-281616
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20201030
FILED AS OF DATE:		20201030
DATE AS OF CHANGE:		20201030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		201274613

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d74072d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 30 October 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g74072g45f49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30&nbsp;October
2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 30</B><B></B><B>&nbsp;October 2020</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology
company, is pleased to provide an update on the ongoing development of its product candidates for the quarter ending 30&nbsp;September 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key
Points </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paxalisib granted special designations by US FDA: Rare Pediatric Disease Designation in DIPG, Orphan Designation
in glioma, and Fast Track Designation in glioblastoma </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New clinical collaboration launched with Dana-Farber Cancer Institute: a phase II study in primary CNS lymphoma,
led by Dr Lakshmi Nayak </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Post-period: completion of a ~$25&nbsp;million financing round and execution of definitive agreement with GCAR to
commence GBM AGILE pivotal study </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner, commented, &#147;the September quarter has been highly productive: we have
launched a new clinical study, and we have seen important recognition by FDA of the drug&#146;s potential in several forms of brain cancer. These achievements leave us ideally positioned as we now transition into the GBM AGILE pivotal study in
glioblastoma. The remainder of this year, and the year ahead, are likely to be rich in data read-outs and in operational progress, as we see paxalisib move rapidly towards commercialization.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FDA Special Designations Awarded </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, Kazia
received Rare Pediatric Disease Designation (RPDD) from the US FDA for paxalisib in the treatment of diffuse intrinsic pontine glioma (DIPG). RPDD is designed to support and encourage the development of drugs for rare childhood illnesses. The key
benefit of it the program is that it allows for the sponsor company to receive a priority review voucher (PRV) at the time of an application for marketing authorization in the paediatric disease. The PRV can be sold to another company and used for
any new drug, and such transactions have historically commanded prices between US$ 68 and 350&nbsp;million. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also in August 2020, Kazia received Fast Track Designation (FTD) from the US FDA for paxalisib in the
treatment of glioblastoma. FTD is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions. It provides Kazia with substantially enhanced
access to FDA, including the ability to submit a &#145;rolling NDA&#146;, in which components of the new drug application can be filed as they become available, increasing efficiency and reducing risk in the approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, and also in August 2020, Kazia received Orphan Drug Designation (ODD) from the US FDA for paxalisib in the treatment of glioma. This encompasses
both DIPG and glioblastoma. The company previously received ODD for the narrower indication of glioblastoma in February 2018. ODD provides access to certain grant funding, a waiver of PDUFA fees at the time&nbsp;of&nbsp;NDA submission (currently
approximately US$&nbsp;3&nbsp;million per indication), and a period of data exclusivity which augments the patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The achievement of these
milestones leaves the paxalisib program well-optimised from a regulatory standpoint:- </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Glioblastoma</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DIPG</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orphan Drug Designation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Fast Track Designation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Rare Pediatric Disease Designation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">n/a</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August 2020</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Phase II Study in Primary CNS Lymphoma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, Kazia launched a new clinical collaboration with Dana Farber Cancer Institute. Under the terms of the collaboration, Dr Lakshmi Nayak will
lead a phase II investigator-initiated clinical trial in primary CNS lymphoma. Dr Nayak is an extensively published clinical researcher in this field, and Dana Farber has a world-leading specialist unit for treatment and research of this disease.
Primary CNS lymphoma is a form of brain cancer that affects approximately 1,500 patients per annum in the United States. It is considered a high-potential target for paxalisib, since three of the four
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> PI3K inhibitors are used to treat forms of lymphoma outside the central nervous system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Broad
Clinical Trial Program on Track </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sponsor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glioblastoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03522298</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance for Clinical Trials in Oncology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brain metastases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03994796</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana-Farber Cancer Institute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Breast cancer brain metastases</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>with Herceptin</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03765983</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana-Farber Cancer Institute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary CNS lymphoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TBD</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">St Jude Children&#146;s Research Hospital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DIPG (childhood brain cancer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03696355</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Memorial Sloan Kettering Cancer Center</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brain metastases</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>with radiotherapy</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT04192981</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Period Events &#150; Successful Capital Raise </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On 1&nbsp;October 2020, Kazia launched a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-three</FONT></FONT> accelerated <FONT
STYLE="white-space:nowrap">non-renounceable</FONT> entitlement offer to raise approximately $25&nbsp;million, before fees. The transaction was fully-underwritten by Bell Potter Securities Limited. The accelerated institutional component closed on
2&nbsp;October 2020, raising approximately $16.4&nbsp;million from institutional investors, representing approximately a 70% <FONT STYLE="white-space:nowrap">take-up.</FONT> The retail component closed on 20&nbsp;October 2020, raising a further
$8.8&nbsp;million, with approximately 32% <FONT STYLE="white-space:nowrap">take-up.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This financing leaves the company well-funded to execute the
GBM AGILE pivotal study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Period Events &#150; GBM AGILE Moves into Operational Phase </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On 16&nbsp;October 2020, the company executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to commence paxalisib&#146;s
participation in the GBM AGILE pivotal study in glioblastoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM AGILE is an international, multi-drug platform study, designed to expedite the approval
of new medicines for glioblastoma. It is run independently of any individual company, under the leadership of some of the world&#146;s premier experts in the field. The study is already ongoing, with thirty sites in the United States and Canada
participating, and the first drug is Bayer&#146;s Stivarga<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (regorafenib). Paxalisib will be the second drug to enter the study. First patient in to the paxalisib arm is expected to occur in
early Q1 CY2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company has no revisions to its prior guidance concerning <FONT STYLE="white-space:nowrap">COVID-19.</FONT> At present, there is limited operational
impact, but Kazia continues to monitor the situation closely. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted in the accompanying Appendix 4C, the company&#146;s cash position as at 30&nbsp;September 2020 was AU$ 6.5&nbsp;million. The company invested AU$
1.6&nbsp;million in research and development activities during 1Q FY2021, and incurred G&amp;A expenses of AU$ 0.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of cash at
30&nbsp;September 2020 and expenditure during the quarter, the Appendix 4C reflects almost three quarters of available funding. However, immediately post-period, the company executed a fully underwritten capital raise which yielded approximately
$25&nbsp;million in new capital, before fees. As a consequence, the company&#146;s operations are well-funded for the foreseeable future. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upcoming Milestones </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key milestones for the next two quarters are as follows:- </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional interim data from the ongoing phase II study of paxalisib in glioblastoma (November 2020 &#150; SNO
Annual Meeting) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initial interim data from the ongoing phase I study of paxalisib in DIPG at St Jude Children&#146;s Research
Hospital (November 2020 &#150; SNO Meeting) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initial interim data from the ongoing phase II study in breast cancer brain metastases at Dana-Farber Cancer
Institute (precise timing remains uncertain due to COVID-related disruption of conference schedules) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Top-line</FONT> final data from the completed phase I study of Cantrixil in
ovarian cancer </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First patient in (FPI) to GBM AGILE registration study for paxalisib in glioblastoma (planned for each Q1 CY2021
in order to avoid Christmas and New Year period) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These milestones are indicative and may be subject to change. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of
oncology indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib (formerly <FONT STYLE="white-space:nowrap">GDC-0084),</FONT> a small molecule inhibitor of the PI3K /
AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data
was reported most recently at AACR in June 2020, and further data is expected in 2H 2020. Five additional studies are in <FONT STYLE="white-space:nowrap">start-up</FONT> or ongoing in other forms of brain cancer. Paxalisib was granted Orphan Drug
Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for
DIPG in August 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRX-E-002-1</FONT></FONT></FONT>
(Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRX-E-002-1</FONT></FONT></FONT> has completed a phase I clinical trial in Australia and the United States with the final data expected in the second
half of calendar 2020. Interim data was presented most recently at the AACR conference in June 2020. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Rule 4.7B </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 4C </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quarterly
cash flow report for entities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>subject to Listing Rule 4.7B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name of entity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ABN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Quarter ended (&#147;current quarter&#148;)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">37 063 259 754</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">30&nbsp;September 2020</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Consolidated statement of cash flows</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;to&nbsp;date<BR>(3 months)</B><br><B>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>1.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;Cash flows from operating activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Receipts from customers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Payments for</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(a)&#8201;&#8202;research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(b)&#8201;&#8202;product manufacturing and operating costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(c)&#8201;&#8202;advertising and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(d)&#8201;&#8202;leased assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(e)&#8201;&#8202;staff costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(f)&#8201;&#8201;administration and corporate costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Dividends received<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>(see note&nbsp;3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Interest received</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Interest and other costs of finance paid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Income taxes paid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Government grants and tax incentives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Other (provide details if material)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>1.9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;Net cash from / (used in) operating activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD COLSPAN="10" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 1</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Consolidated statement of cash flows</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current&nbsp;quarter</B><br><B>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;to&nbsp;date</B><br><B>(3 months)</B><br><B>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>2.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash flows from investing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Payments to acquire or for:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&#8194;&#8201;&#8202;entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&#8194;&#8201;&#8202;businesses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&#8194;&#8201;&#8202;property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(d)&#8194;&#8201;&#8202;investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(e)&#8194;&#8201;&#8202;intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(f)&#8194;&#8201;&#8201;other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from disposal of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&#8194;&#8201;&#8202;entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&#8194;&#8201;&#8202;businesses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&#8194;&#8201;&#8202;property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(d)&#8194;&#8201;&#8202;investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(e)&#8194;&#8201;&#8202;intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(f)&#8194;&#8201;&#8201;other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash flows from loans to other entities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dividends received (see note&nbsp;3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Other (provide details if material)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>2.6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Net cash from / (used in) investing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>3.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash flows from financing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from issues of equity securities (excluding convertible debt securities)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from issue of convertible debt securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from exercise of options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transaction costs related to issues of equity securities or convertible debt securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from borrowings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Repayment of borrowings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transaction costs related to loans and borrowings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dividends paid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Other (provide details if material)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>3.10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Net cash from / (used in) financing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Consolidated statement of cash flows</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current&nbsp;quarter</B><br><B>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;to&nbsp;date</B><br><B>(3 months)</B><br><B>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>4.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Net increase / (decrease) in cash and cash equivalents for the period</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash and cash equivalents at beginning of period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) operating activities (item&nbsp;1.9 above)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) investing activities (item&nbsp;2.6 above)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) financing activities (item&nbsp;3.10 above)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Effect of movement in exchange rates on cash held</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>4.6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash and cash equivalents at end of period</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>5.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>Reconciliation of cash and cash equivalents</B><B><BR></B>at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B><BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Previous&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B><BR>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bank balances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Call deposits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bank overdrafts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Other (provide details)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>5.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash and cash equivalents at end of quarter (should equal item&nbsp;4.6 above)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,764</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>6.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>Payments to related parties of the entity and their associates</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B><BR>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aggregate amount of payments to related parties and their associates included in item&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aggregate amount of payments to related parties and their associates included in item&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="10"><I>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</I></TD>
<TD VALIGN="top"><I>&nbsp; </I>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt"><B>7.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing facilities<BR></B><I>Note: the term &#147;facility&#146; includes all forms of financing arrangements available to
the<BR>entity.</I><B></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Add notes as necessary for an understanding of the sources of finance available to the<BR>entity.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;facility<BR>amount&nbsp;at</B><br><B>quarter end<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B><br><B>drawn&nbsp;at</B><br><B>quarter&nbsp;end<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Loan facilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Credit standby arrangements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Other (please specify)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Total financing facilities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Unused financing facilities available at quarter end</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="8">Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or
are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>Estimated cash available for future operating activities</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) operating activities (item&nbsp;1.9)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash and cash equivalents at quarter end (item&nbsp;4.6)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unused finance facilities available at quarter end (item&nbsp;7.5)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Total available funding (item&nbsp;8.2 + item&nbsp;8.3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Estimated quarters of funding available (item&nbsp;8.4 divided by item&nbsp;8.1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="8"><I>Note: if the entity has reported positive net operating cash flows in item&nbsp;1.9, answer item&nbsp;8.5 as &#147;N/A&#148;. Otherwise, a figure for the estimated quarters of funding available must be included in
item&nbsp;8.5.</I></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If item&nbsp;8.5 is less than 2&nbsp;quarters, please provide answers to the following questions:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">8.6.1&#8194;&#8201;&#8201;Does the entity expect that it will continue to have the
current level of net operating cash flows for the time being and, if not, why not?</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&#8194;&#8201;&#8201;&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Answer: Cash
outflows are likely to increase as the Company proceeds with the GBM Agile trial</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">8.6.2&#8194;&#8201;&#8201;Has the entity taken any steps, or does it propose to take any steps, to raise further cash
to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Answer: The Company raised $25.2 million (before costs) in October
2020 in order to provide funding for the GBM Agile trial, as well as further working capital.</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">8.6.3&#8194;&#8201;&#8201;Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Answer: Yes</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><I>Note: where item&nbsp;8.5 is less than 2&nbsp;quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compliance statement </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This statement has been prepared in accordance with accounting standards and policies which comply with Listing
Rule 19.11A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This statement gives a true and fair view of the matters disclosed. </P></TD></TR></TABLE>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">30&nbsp;October 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Authorised&nbsp;by:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Name&nbsp;of&nbsp;body&nbsp;or&nbsp;officer&nbsp;authorising&nbsp;release&nbsp;&#150;&nbsp;see&nbsp;note&nbsp;4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notes </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This quarterly cash flow report and the accompanying activity report provide a basis for informing the market
about the entity&#146;s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing
Rules is encouraged to do so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the
definitions in, and provisions of, <I>AASB 107: Statement of Cash Flows </I>apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dividends received may be classified either as cash flows from operating activities or cash flows from
investing activities, depending on the accounting policy of the entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this report has been authorised for release to the market by your board of directors, you can insert here:
&#147;By the board&#148;. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: &#147;By the [<I>name of board committee</I> &#150; <I>eg Audit and Risk Committee</I>]&#148;. If it has
been authorised for release to the market by a disclosure committee, you can insert here: &#147;By the Disclosure Committee&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this report has been authorised for release to the market by your board of directors and you wish to hold
yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council&#146;s <I>Corporate Governance Principles and Recommendations</I>, the board should have received a declaration from its CEO and CFO that, in their opinion,
the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the
basis of a sound system of risk management and internal control which is operating effectively. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 5</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g74072g45f49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g74072g45f49.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( (X#- ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\)P*3<*24XC;Z5^:_Q<_X.2O
M_P (OC%XR\&W'PQ\:7UUX+\0:CX>GNH;VT2*YELKJ6V>1 S;@K-$6 /.".^:
MUI49U':"N9U*T*:O-V/TIW"C<*_+?_B*,\!?]$G\=_\ @PLO_BZ/^(HOP#_T
M2GQY_P"#"Q_^+K7ZCB/Y&<_UZA_.C]2-PHW"ORW_ .(HOP#_ -$I\>?^!]C_
M /%T?\11G@+_ *)/X[_\&%E_\71]1Q'\C#Z]0_G1^I&X4;A7Y;_\11G@(_\
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M1G@'_HE'CS_P86/_ ,71]1Q'\C#Z]0_G7XGZD;A1N%?EO_Q%%^ ?^B4^//\
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M'V/_ ,71_P 11?@'_HE/CS_P86/_ ,73^HXC^1C^O4/YU^)^I&X4;A7Y;_\
M$49X"_Z)/X[_ /!A9?\ Q='_ !%&> 3_ ,TH\>?^#"Q_^+I?4<1_(Q?7J'\Z
M_$_4C<*-PK\M_P#B*+\ _P#1*?'G_@?8_P#Q='_$49X"_P"B3^.__!A9?_%T
M?4<1_(P^O4/YU^)^I&X4;A7Y;_\ $49X"_Z)/X[_ /!A9?\ Q='_ !%%^ ?^
MB4^//_ ^Q_\ BZ/J.(_D8?7J'\Z_$_4C<*-PK\M_^(HOP#_T2GQY_P"#"Q_^
M+H_XBC/ 7_1)_'?_ (,++_XNCZCB/Y&'UZA_.OQ/U(W"C<*_+?\ XBB_ /\
MT2GQY_X,+'_XNC_B*+\ _P#1*?'G_@?8_P#Q='U'$?R,/KU#^='ZD;A1N%?E
MO_Q%&> O^B3^._\ P867_P 71_Q%&> O^B4>._\ P86/_P 71]1Q'\C#Z]0_
MG7XGZD;A1N%?EO\ \11?@'_HE/CS_P #['_XNC_B*,\!#_FE'CS_ ,&%C_\
M%T?4<1_(P^O4/YT?J1N%&X5^6_\ Q%&> O\ HD_CO_P867_Q='_$47X!_P"B
M4^//_!A8_P#Q='U'$?R,/KU#^=?B?J1N%&X5^6__ !%%^ ?^B4^//_ ^Q_\
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MC/ 7_1*/'G_@PL?_ (NCZCB/Y&'UZA_.OQ/U(W"C<*_+?_B*+\ _]$I\>?\
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MP%_T2?QW_P"#"R_^+H^HXC^1B^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X\_\
M ^Q_^+H_XBB_ /\ T2GQY_X,+'_XNG]1Q'\C']>H?SK\3]2-PHW"ORW_ .(H
MSP%_T2?QW_X,++_XNC_B*+\ _P#1*?'G_@PL?_BZ7U'$?R,7UZA_.OQ/U(W"
MC<*_+?\ XBB_ /\ T2GQY_X'V/\ \71_Q%&> O\ HE'CO_P86/\ \71]1Q'\
MC#Z]0_G7XGZD;A1N%?EO_P 11G@+_HE'CO\ \&%C_P#%T?\ $47X!_Z)3X\_
M\#['_P"+H^HXC^1A]>H?SH_4C<*-PK\M_P#B*,\ C_FE'CS_ ,&%C_\ %T?\
M11G@+_HD_CO_ ,&%E_\ %T?4<1_(P^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X
M\_\ !A8__%T?\11?@'_HE/CS_P #['_XNCZCB/Y&/Z]0_G1^I&X4;A7Y;_\
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M-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\
M?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_
MW:,?[M'_ 'S1_P!\T &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,
M?[M'_?-'_?- !C_=HQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?
M]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T
M?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_W:,?[M'_ 'S1_P!\
MT &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,?[M'_?-'_?- !C_=
MHQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_
MNT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_W
MS1_WS0 8_P!VC'^[1_WS1_WS0 ZV'^D1_=^]VK^E3_@CU_RBN_9[_P"Q!TC_
M -)8Z_FKM_\ CXC^[]ZOZ5/^"/7_ "BN_9[_ .Q!TC_TECKQLZ_AQ]?T1ZN3
M_'+T_5GTA1117SA[XV3_ %;?2OY8?VSSC]M[X[?=_P"2F>*.O_89O*_J>D_U
M;?2OY8?VSSC]M[X[<_\ -3/%'_IYO*]C)?XK]/U/'SC^''U/.=W^[1N_W:-W
M^T/RHW?[0_*OI#PPW?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@!UL?](C^[][M7]*G_  1Z_P"45W[/?_8@
MZ1_Z2QU_-7;G-Q'R/O5_2I_P1Z_Y17?L]_\ 8@Z1_P"DL=>-G7\./K^B/6RC
MXY>GZL^D****^</>&R?ZMOI7\L/[9YQ^V]\=N?\ FIGBCM_U&;NOZGI/]6WT
MK^6']L\X_;>^.W/_ #4SQ1V_ZC-Y7LY+_%?I^IX^<?PX^IYSN_VOTHW?[7Z4
M;O\ :_2C=_M?I7T9X8;O]K]*-W^U^E&[_:_2C=_M?I0 ;O\ :_2C=_M?I06]
M_P!*]NT[]A_4-0_X)XZA^T"OB73_ "K#4VB_X1EK<&ZETX:A_9C:CYBR;MBW
M@*&(1Y*JS;^1B)5(QMS/?0J,7+X?4\1W?[7Z4;O]K]*]R^*?[%EI\&OV:M$\
M;ZM\1]"7Q5KWA#2O'FG^$'LGBN-2TF]E,:+973LL5W?1 ;Y;95QM/$FTAJT_
MVC/^">M_\ /!"^(H?%2^)M)\4:WI.C_#633]+8R_$>*^LH[QKNWA\TR1Q0K<
M16^%$IDG94#*<9S6*I-V3-/J]1=#YZW?[7Z4;N>M>H?LY_LJ:]^TSI'Q(_X1
M\S2>(OA_9:;-;:.MH9)-9NK[41816V[<OV?#X=G<-M (*CDKW?PT_8F\#_$3
M]KC5/@Y;_&2:;7H=;A\/:+=Z=X(N=2A\077E.U\%\NX BAM&20&9CB1$,J;5
MXISQ$(WOTW%&A.232WV/G3=S][]*-W^U^E>__L^_L&_\-*ZG\7E\.^.-/DT_
MX=S7-GX9NDTYYQ\0[I(=1N;>WM,2 1F6TL#,&;?@2J<$Y)\;^&G@L?$W1/&5
MY#??91X2\+-XF4&$O]L OK"U\GJ-G_'[OW8/,6W&&R"->#Z[?KL'L)JUUO\
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M?I1N_P!K]*-W^U^E&[_:_2@ W?[7Z4;O]K]*-W^U^E&[_:_2@ W?[7Z4;O\
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M1#ACDAB-PKTJ.7WA"M5DHP<K/NO.Q\WBL_:KU<%A*;G5C#FC?2+?:YX+XA\
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M"VT'@MC )&2,C/0?\,]_$3_HG_CS_P )V]_^-5,IQ3LV-1;V.1W?[7Z4;O\
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M_+#^V?\ \GO?';[W_)3/%'_IYO*]C)?XK]/U/'SC^''U/.<^[?E1GW;\J/\
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MY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\ OJ@ S[M^5&?=ORH_[ZH_[ZH
M,^[?E1GW;\J/^^J/^^J #/NWY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\
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M;M2\;LNK^(U1OFM]*A?]W$3U7[1<*J\9W1PSCCJ/QI<_,WS-U)SLVY_#H*]
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M^*O!G@%=8C\3>)=0\'1>'[W7KFXFU"YC@L8M/749;=HFM-0FNKBXE2"'9&\
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MV?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H
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MXJ_I4_X(]?\ **[]GO\ [$'2/_26.OYJ[8?Z1'POWNU?TJ?\$>O^45W[/?\
MV(.D?^DL=>-G7\./K^B/6RCXY>GZL^D****^</>&SAC"VW[V.*_'/X]_\&W?
MQ/\ BU^T)\1/&%C\0O =K8^,_%FK^(;:WN+>[::WBO+Z>Y2-RJXW*LH4XR,@
M\D5^QQ&10%Q6]#$5*+YJ;,:V'A55IH_$?_B%_P#BS_T4GX<_^ M[_P#$T?\
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M]_P#^S*';\6?B/\ \0P'Q8_Z*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M]_P#^S:';\6?B.?^#8#XL9_Y*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M/?\  /[-H=OQ9^(Y_P"#7_XLX_Y*3\.?_ 6]_P#B:/\ B& ^+'_12OAS_P"
MU[_\37[<44?VIB>_X!_9M#M^+/Q''_!L!\6/^BE?#G_P%O?_ (FC_B%_^+/_
M $4GX<_^ M[_ /$U^W%%']J8GO\ @']FT.WXL_$?_B& ^+'_ $4KX<_^ M[_
M /$T?\0P'Q8_Z*5\.?\ P&O?_B:_;BBC^U,3W_ /[-H=OQ/Q'_XA@/BS_P!%
M)^'/_@+>_P#Q-!_X-@/BQ_T4KX<_^ M[_P#$U^W%%']J8GO^ ?V;0[?BS\1_
M^(8#XL?]%*^'/_@->_\ Q- _X-@/BQ_T4KX<_P#@+>__ !-?MQ11_:F)[_@'
M]FT.WXL_$?\ XA?_ (L_]%)^'/\ X"WO_P 31_Q# ?%C_HI7PY_\!KW_ .)K
M]N**/[4Q/?\  /[-H=OQ9^)$7_!L#\6(Y5;_ (63\.SM.3BVO0?SV&OUA_87
M^ NH?LM?L<_#/X;ZM?6.IZEX&\.66B7-W9*RV]R\$2QEXP_S!3C@-S7JI7=2
8@8KGKXNK6_B,Z*.%ITM8(****YSH/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
